Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Moderate Buy" by Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $38.00.

A number of research analysts have issued reports on INO shares. Royal Bank of Canada decreased their price target on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a "sector perform" rating for the company in a report on Friday, November 15th. HC Wainwright reduced their price target on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a "neutral" rating for the company in a research report on Monday, November 18th. Finally, Oppenheimer cut their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an "outperform" rating on the stock in a research note on Monday, November 18th.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in INO. Bank of New York Mellon Corp acquired a new position in Inovio Pharmaceuticals during the 2nd quarter worth $661,000. Signature Estate & Investment Advisors LLC purchased a new stake in Inovio Pharmaceuticals in the 2nd quarter valued at approximately $88,000. Rhumbline Advisers boosted its stake in shares of Inovio Pharmaceuticals by 5,943.0% during the 2nd quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company's stock worth $311,000 after purchasing an additional 37,857 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Inovio Pharmaceuticals by 62.2% during the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company's stock worth $255,000 after purchasing an additional 12,100 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. purchased a new stake in Inovio Pharmaceuticals in the second quarter valued at approximately $184,000. Hedge funds and other institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Trading Down 6.6 %

Shares of INO stock traded down $0.27 during trading hours on Thursday, reaching $3.76. 1,114,534 shares of the company's stock were exchanged, compared to its average volume of 410,231. Inovio Pharmaceuticals has a 1 year low of $3.73 and a 1 year high of $14.75. The stock has a market cap of $98.14 million, a PE ratio of -1.09 and a beta of 0.75. The stock's fifty day moving average price is $4.95 and its two-hundred day moving average price is $7.21.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.